We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

117 hedge funds and large institutions have $490M invested in Rigel Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

73% more call options, than puts

Call options by funds: $8.8M | Put options by funds: $5.09M

42% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 31

0.12% more ownership

Funds ownership: 9.29% → 9.41% (+0.12%)

3% less funds holding

Funds holding: 121 → 117 (-4)

7% less capital invested

Capital invested by funds: $528M → $490M (-$37.5M)

16% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 19

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
117
Holders Change
-4
Holders Change %
-3.31%
% of All Funds
2.68%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
16
Increased
44
Reduced
31
Closed
19
Calls
$8.8M
Puts
$5.09M
Net Calls
+$3.71M
Net Calls Change
+$2.62M

Top Buyers

1
BC
Boxer Capital
California
+$8.01M
2
State Street
State Street
Massachusetts
+$4.04M
3
Citigroup
Citigroup
New York
+$3.25M
4
GPP
Great Point Partners
Connecticut
+$2.77M
5
JP Morgan Chase
JP Morgan Chase
New York
+$2.61M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$6.27M
2
Citadel Advisors
Citadel Advisors
Florida
-$3.67M
3
SCM
Sio Capital Management
New York
-$3.43M
4
GTC
Ghost Tree Capital
New York
-$3.2M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$78.2M +$458K +11,446 +0.5%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$73M +$1.27M +31,642 +2%
BlackRock
3
BlackRock
New York
$39.2M -$584K -14,580 -1%
GPP
4
Great Point Partners
Connecticut
$30.4M +$2.77M +69,087 +9%
Vanguard Group
5
Vanguard Group
Pennsylvania
$23.1M +$1.28M +32,066 +5%
BC
6
Boxer Capital
California
$18.2M +$8.01M +200,000 +64%
O
7
OppenheimerFunds
New York
$17.7M +$14.1K +352 +0.1%
State Street
8
State Street
Massachusetts
$17.7M +$4.04M +100,985 +25%
Millennium Management
9
Millennium Management
New York
$14.2M -$6.27M -156,566 -28%
PAI
10
Palo Alto Investors
California
$14M +$122K +3,051 +0.8%
NMC
11
NEA Management Company
Maryland
$11.5M – – –
Citadel Advisors
12
Citadel Advisors
Florida
$11.2M -$3.67M -91,608 -23%
MWNA
13
Marshall Wace North America
New York
$10.7M -$1.02M -25,468 -8%
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$9.51M +$7.25K +181 +0.1%
RSCM
15
Rock Springs Capital Management
Maryland
$9.12M +$400K +10,000 +4%
BBA
16
Baker Bros. Advisors
New York
$8.92M – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$7.16M +$2.61M +65,286 +48%
Northern Trust
18
Northern Trust
Illinois
$6.29M +$147K +3,684 +2%
RPAM
19
Rhenman & Partners Asset Management
Sweden
$5.73M -$1.26M -31,506 -16%
CS
20
Candriam SCA
Luxembourg
$5.33M +$1.14M +28,500 +23%
Deutsche Bank
21
Deutsche Bank
Germany
$4.62M +$916K +22,873 +21%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$4.51M +$103K +2,572 +2%
Hudson Bay Capital Management
23
Hudson Bay Capital Management
Connecticut
$4.42M – – –
Citigroup
24
Citigroup
New York
$3.5M +$3.25M +81,203 +456%
Barclays
25
Barclays
United Kingdom
$3.28M +$2M +50,068 +118%
1
2 3 4 5

RIGL Hedge Fund Activity: Q1 2018 in Review

117 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2018, worth a combined $490M — down 7.1% from $528M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of RIGL and 16 opened new positions — a net loss of 3 holders — while 31 trimmed existing stakes and 44 added.

The largest buyer was Boxer Capital, adding an estimated $8.01M. The largest seller was Millennium Management, cutting an estimated $6.27M.

  • 117 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2018, down from 121 in Q4 2017.
  • Funds reported $490M of Rigel Pharmaceuticals stock for Q1 2018, down 7.1% quarter-over-quarter.
  • 16 funds opened new Rigel Pharmaceuticals positions in Q1 2018 and 19 closed out, a net change of -3 holders.
  • The largest Rigel Pharmaceuticals buyer in Q1 2018 was Boxer Capital, an estimated $8.01M added.
  • The largest Rigel Pharmaceuticals seller in Q1 2018 was Millennium Management, an estimated $6.27M sold.

Based on aggregated 13F filings for Q1 2018.